Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIOSynVax Bird Flu vaccine
- Development stage
- Preclinical
- Lead developer
- DIOSynVax
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal, Intramuscular (potential)
01
Overview
The DIOSynVax Bird Flu vaccine is a next-generation, broadly protective mRNA-based influenza vaccine candidate developed to provide immunity against a wide range of H5 avian influenza virus clades. It leverages the proprietary "Digital Immune Optimized Synthetic Vaccine" (DIOSynVax) platform, which uses advanced artificial intelligence-driven antigen design to create synthetic antigens capable of inducing strong neutralizing antibody responses across diverse H5 subtypes. The technology aims to overcome the limitations of traditional strain-specific vaccines by offering broad protection with a single formulation. The delivery system is being developed in partnership with ACM Biolabs and may enable mucosal administration via nasal spray for improved uptake and temperature stability. Preclinical studies have demonstrated robust efficacy and safety in animal models; the candidate is ready for human clinical trials[1][5][6][9].
- Brand names
- DIOSynVax Bird Flu vaccine
- Other names
- Universal bird flu vaccinepan-Bird Flu (H5Nx) vaccineDigital Immune Optimized Synthetic Vaccine (DIOSynVax) platform bird flu vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on DIOSynVax Bird Flu vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIOSynVax Bird Flu vaccine.